Effects of the Hippo Signaling Pathway in Human Gastric Cancer

  • Zhou, Guang-Xi (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Li, Xiao-Yu (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Zhang, Qi (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Zhao, Kun (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Zhang, Cui-Ping (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Xue, Chang-Hu (College of Food Science and Engineering, Ocean University of China) ;
  • Yang, Kun (The Core Laboratory, The Affiliated Hospital of Qingdao University Medical College) ;
  • Tian, Zi-Bin (Department of Gastroenterology, The Affiliated Hospital of Qingdao University Medical College)
  • Published : 2013.09.30


Background/Aim: The Hippo signaling pathway is a newly discovered and conserved signaling cascade, which regulates organ size control by governing cell proliferation and apoptosis. This study aimed to investigate its effects in human gastric cancer. Methods: Tumor tissues (n=60), adjacent non-tumor tissues (n=60) and normal tissues (n=60) were obtained from the same patients with primary gastric cancer (GC). In addition, 70 samples of chronic atrophic gastritis (CAG) tissues were obtained from patients with intestinal metaplasia (IM) by endoscopic biopsy. Hippo signaling molecules, including Mst1, Lats1, YAP1, TAZ, TEAD1, Oct4 and CDX2, were determined by quantitative polymerase chain reaction (qPCR). Protein expression of Mst1, Lats1, YAP1, TEAD1 and CDX2 was assessed by immunohistochemistry and Western blotting. Results: Mst1, Lats1 and Oct4 mRNA expression showed an increasing tendency from GC tissues to normal gastric tissues, while the mRNA expression of YAP1, TAZ and TEAD1 was up-regulated (all P<0.01). Mst1 and Lats1 protein expression presented a similar trend with their mRNA expression. In addition, YAP1 and TEAD1 protein expression in GC was significantly higher than in the other groups (all P<0.01). CDX2 mRNA and protein expression in the CAG group were higher than in the other groups (all P<0.01). In GC, mRNA expression of Mst1, Lats1, Oct4, YAP1, TAZ, TEAD1 and CDX2 had a close correlation with lymphatic metastasis and tumor TNM stage (all P<0.01). Furthermore, protein expression of Mst1, Lats1, YAP1, TAZ, TEAD1 and CDX2 had a close correlation between each other (P<0.05). Conclusion: The Hippo signaling pathway is involved in the development, progression and metastasis of human gastric cancer. Therefore, manipulation of Hippo signaling molecules may be a potential therapeutic strategy for gastric cancer.


Hippo signaling pathway;gastric cancer;chronic atrophic gastritis;intestinal metaplasia


  1. Freund JN, Domon-Dell C, Kedinger M, Duluc I (1998). The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol, 76, 957-69
  2. Barros R, da Costa LT, Pinto-de-Sousa J, et al (2011). CDX2 auto-regulation in human intestinal metaplasia of the stomach: impact on the stability of the phenotype. Gut, 60, 290-8.
  3. Chu J, Qin R, Wang N, et al (2011). Expression and significance of CDX2 and elaudin-3 in gastric carcinoma and paracancer tissue. J Clin Exp Pathol, 27, 1280-5.
  4. Harvey KF, Pfleger CM, Hariharan IK (2003). The Drosophila Mst Ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell, 114, 457-67.
  5. Kang JM, Lee BH, Kim N, et al (2011). CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer. J Korean Med Sci, 26, 647-53.
  6. Nishioka N, Inoue K, Adachi K, et al (2009). The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell, 16, 398-410.
  7. Liu X, Zhang X, Zhan Q, et al (2012). CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. Cancer Biol Ther, 13, 1152-7.
  8. Matsuoka J, Yashiro M, Sakurai K, et al (2012). Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res, 174, 130-5.
  9. Morrow DJ, Avissar NE, Toia L, et al (2009). Pathogenesis of Barrett's esophagus: Bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophagea cells. Surgery, 146, 714-22.
  10. Pan D (2010). The hippo signaling pathway in development and cancer. Dev Cell, 19, 491-505.
  11. Tajima Y, Yamazaki K, Makino R, et al (2006). Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic Background. Clin Cancer Res, 12, 6469-79.
  12. Trosko JE (2006). From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion. Ann N Y Acad Sci, 1089, 36-58.
  13. Visser-Grieve S, Zhou Z, She YM, et al (2011). LATS1 Tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization. Cell Res, 21, 1513-6.
  14. Wei W, Zhang C, Zhang Q, et al (2012). Expression of Hippo signaling molecules in gastric carcinogenesis. World Chin J Digestol, 20, 3027-32.
  15. Wen J, Park JY, Park KH, et al (2010). Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas, 39, 622-6.
  16. Zhao B, Lei QY, Guan KL (2008). The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol, 20, 638 - 46.
  17. Xu Z, Zhu J, Zhang Q, et al (2011). A breakdown of the Hippo pathway in gastric cancer. Hepatogastroenterology, 58, 1611-7.
  18. Yang L (2006). Incidence and mortality of gastric cancer in China. World J Gastroenterol, 12, 17-20.
  19. Zeng Q, Hong W (2008). The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell, 13, 188-92.
  20. Zhao B, Wei X, Li W, et al (2007). Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev, 21, 2747-61.
  21. Zheng T, Wang J, Jiang H, et al (2011). Hippo signaling in oval cells and hepatocarcinogenesis. Cancer Letters, 302, 91-9.

Cited by

  1. Comparative Analysis of Oct4 in Different Histological Subtypes of Esophageal Squamous Cell Carcinomas in Different Clinical Conditions vol.15, pp.8, 2014,
  2. Overexpression of YAP1 is Correlated with Progression, Metastasis and Poor Prognosis in Patients with Gastric Carcinoma vol.20, pp.4, 2014,
  3. Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer vol.35, pp.7, 2014,
  4. Methylation-associated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma vol.45, pp.6, 2014,
  5. Promyelocytic leukemia protein enhances apoptosis of gastric cancer cells through Yes-associated protein vol.36, pp.10, 2015,
  6. MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1 vol.36, pp.9, 2015,
  7. Emerging role of Hippo pathway in gastric and other gastrointestinal cancers vol.22, pp.3, 2016,
  8. Emerging role of Hippo signalling pathway in bladder cancer vol.22, pp.1, 2017,
  9. TAZ overexpression is associated with epithelial-mesenchymal transition in cisplatin-resistant gastric cancer cells vol.51, pp.1, 2017,
  10. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway vol.7, pp.1, 2017,
  11. Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma pp.1532-2807, 2017,
  12. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis vol.17, pp.1, 2016,
  13. miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype vol.14, pp.4, 2017,
  14. Inhibitory effect and mechanism of exogenous mammalian sterile 20-like kinase 1 on the growth of human colorectal cancer vol.13, pp.4, 2017,
  15. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors vol.10, pp.3, 2018,
  16. Roles of the MST1-JNK signaling pathway in apoptosis of colorectal cancer cells induced by Taurine vol.13, pp.1, 2018,
  17. Clinical implications of the Hippo-YAP pathway in multiple cancer contexts vol.51, pp.3, 2018,
  18. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma vol.10, pp.2, 2019,